Drug intelligence / Profile preview

human rabies vaccine (vero cells)

Development stage
Unknown
Lead developer
Liaoning Chengda Biotechnology
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Human rabies vaccine (vero cells) is a **purified inactivated viral vaccine** produced by growing the rabies virus in Vero cell cultures, followed by multiple stages of clarification, concentration, inactivation (typically with β-propiolactone), and chromatographic purification to remove impurities such as residual host cell DNA or proteins. It is indicated for **pre-exposure and post-exposure prophylaxis of rabies** in humans. These vaccines induce the production of neutralizing antibodies targeting the rabies virus glycoprotein, the principal antigen that elicits a protective immune response. The vaccines consistently yield seroconversion in nearly all recipients within two weeks and are widely used due to safety, immunogenicity, and suitability for large-scale production. Multiple brands exist, including SPEEDA PVRV (Liaoning Chengda Biology), VERORAB (Sanofi), and PVRV-NG (Sanofi).

Brand names
SPEEDA PVRVVERORABRabipurPVRV-NGPVRV-NG2PVRV-NG-2PVRV-NG 2
Other names
purified vero cell rabies vaccinevero cell rabies vaccinePVRV
02

Targets

RABV-G (Rabies virus glycoprotein)

Beyond the preview

Go deeper on human rabies vaccine (vero cells).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on human rabies vaccine (vero cells).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call